GlassScriptPhysician profile
John P Milliken
NPI 1013048057
$10,771.72
in general payments reported to CMS, 2019-2025
39 companies · $1,815 in 2025
The $1,815 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,585 · 2020: $687 · 2021: $1,342 · 2022: $1,774 · 2023: $1,834 · 2024: $1,736 · 2025: $1,815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,267 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,267.06 |
| Education | $116.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,746.99 | 2019-2025 | |
| Janssen Biotech, INC. | $1,327.41 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,099.99 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $890.89 | 2019-2025 | Xifaxan |
| Pfizer INC. | $664.21 | 2019-2025 | |
| Gilead Sciences, INC. | $601.21 | 2019-2025 | Livdelzi |
| Merck Sharp & Dohme LLC | $475.14 | 2019-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $420.79 | 2019-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $242.02 | 2019-2023 | Rebyota |
| Braintree Laboratories, INC. | $202.45 | 2019-2023 | Sutab, Suflave |
| Genzyme Corporation | $190.75 | 2022-2025 | |
| Organon LLC | $189.31 | 2023-2025 | Hadlima, Renflexis |
| Amgen INC. | $176.93 | 2023-2025 | Amjevita, Avsola |
| Madrigal Pharmaceuticals | $173.07 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $166.42 | 2021-2025 | Iqirvo, Bylvay |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $122.57 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $121.87 | 2022-2023 | |
| Daiichi Sankyo INC. | $116.10 | 2021-2025 | Injectafer |
| Lilly USA, LLC | $93.93 | 2024-2025 | Omvoh |
| Celgene Corporation | $84.97 | 2021-2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $75.34 | 2021-2023 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $67.43 | 2022-2025 | Dupixent |
| Alnylam Pharmaceuticals INC. | $63.64 | 2021-2023 | Givlaari |
| Medtronic, INC. | $62.61 | 2023-2024 | Endoflip, Eleview, Gi Genius |
| Qol Medical, LLC | $60.88 | 2023 | Sucraid |
| Ardelyx, INC. | $60.04 | 2023-2025 | Ibsrela |
| Ucb, INC. | $44.37 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.27 | 2023-2024 | Cyltezo |
| Shire North American Group INC | $31.27 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $23.43 | 2025 | |
| Exact Sciences Corporation | $22.22 | 2025 | The Cologuard Plus Collection Kit |
| Pharmacosmos Therapeutics INC. | $18.44 | 2025 | Monoferric |
| E.R. Squibb & Sons, L.L.C. | $17.75 | 2021 | |
| Allergan, INC. | $15.40 | 2019 | |
| Lucid Diagnostics INC. | $14.42 | 2024 | |
| Capsovision, INC. | $14.40 | 2024 | Capsocam Plus |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 | |
| Digestive Care, INC. | $9.64 | 2025 | Pertzye |
| Janssen Scientific Affairs, LLC | $8.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Milliken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.